Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
Cipla
Chinese Patent Office
Mallinckrodt
Express Scripts
Daiichi Sankyo
Moodys
US Department of Justice

Generated: October 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NEVANAC

« Back to Dashboard

Clinical Trials for NEVANAC

Trial ID Title Status Sponsor Phase Summary
NCT00332774 Nevanac 3-Month Safety Study With QID Dosing Completed Alcon Research Phase 3 The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.
NCT00333255 Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery Completed Alcon Research Phase 3 The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.
NCT00347204 Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK Completed Allergan Phase 4 To determine the ability of two topical Nonsteroidal Anti-inflammatory drops (Acular LS & Nevanac) to help control pain following Photorefractive Keratectomy (PRK).
NCT00347204 Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK Completed Center For Excellence In Eye Care Phase 4 To determine the ability of two topical Nonsteroidal Anti-inflammatory drops (Acular LS & Nevanac) to help control pain following Photorefractive Keratectomy (PRK).
NCT00348582 Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery Completed Innovative Medical Phase 4 The purpose of this study is to compare the clinical outcomes, safety and efficacy in patients randomized to receive either ketorolac or nepafanac following cataract surgery.
NCT00377546 Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1% Completed Innovative Medical Phase 4 To compare the penetration of three different NSAIDs.
NCT00780780 Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema Unknown status Federal University of São Paulo Phase 3 Diabetics retinopathy remains the major threat to sight in the working age population in the developed world. Furthermore, it is increasing as a major cause of blindness in other parts of the world, especially developing countries. Diabetic macular edema (DME) is a manifestation of diabetic retinopathy that produces loss of central vision. The triamcinolone intravitreal injection (1-4mg) is indicated to treatment of diabetic macular edema and it is considered an important treatment since it improves the visual acuity of patients with resolution of edema. Nepafenac is a non-steroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop (0.1% solution). Nepafenac is manufactured by Alcon as Nevanac. It is approved by FDA as well as ANVISA. Pre-clinical studies suggest this medication showed efficacy to treat ocular posterior segment inflammation. The purpose of this study is evaluate the efficacy of intravitreal triamcinolone associated with nepafenac eye drops as treatment of diabetic macular edema.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for NEVANAC

Condition Name

Condition Name for NEVANAC
Intervention Trials
Cataract 6
Cystoid Macular Edema 2
Cataracts 2
Myopia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for NEVANAC
Intervention Trials
Cataract 9
Macular Edema 7
Edema 5
Inflammation 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for NEVANAC

Trials by Country

Trials by Country for NEVANAC
Location Trials
United States 9
Brazil 3
Malaysia 2
Mexico 2
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for NEVANAC
Location Trials
Texas 3
Pennsylvania 2
California 1
Illinois 1
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for NEVANAC

Clinical Trial Phase

Clinical Trial Phase for NEVANAC
Clinical Trial Phase Trials
Phase 4 13
Phase 3 4
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for NEVANAC
Clinical Trial Phase Trials
Completed 15
Unknown status 3
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for NEVANAC

Sponsor Name

Sponsor Name for NEVANAC
Sponsor Trials
Alcon Research 4
Allergan 3
Frank A. Bucci, Jr., M.D. 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for NEVANAC
Sponsor Trials
Other 14
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Fish and Richardson
Citi
Baxter
Chinese Patent Office
Accenture
AstraZeneca
Julphar
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.